Elias Karam, Hematology-Medical Oncology Fellow at Gustave Roussy, shared a post on LinkedIn:
“Live from ESMO GI 2025 Barcelona
New HCC treatments:
- Novel checkpoints (TIGIT, TIM-3)
- CAR-T, TCR, bispecific engagers
- Targeting β-catenin, HDAC, oncolytic viruses
Focus: 5-year survival, cure, QoL.”
More posts featuring ESMOGI25